Intranasal Prime–Boost with Spike Vectors Generates Antibody and T-Cell Responses at the Site of SARS-CoV-2 Infection.

MLA

Metko, Muriel, et al. “Intranasal Prime–Boost with Spike Vectors Generates Antibody and T-Cell Responses at the Site of SARS-CoV-2 Infection.” Vaccines, vol. 12, no. 10, Oct. 2024, p. 1191. EBSCOhost, https://doi.org/10.3390/vaccines12101191.

APA

Metko, M., Tonne, J., Veliz Rios, A., Thompson, J., Mudrick, H., Masopust, D., Diaz, R. M., Barry, M. A., & Vile, R. G. (2024). Intranasal Prime–Boost with Spike Vectors Generates Antibody and T-Cell Responses at the Site of SARS-CoV-2 Infection. Vaccines, 12(10), 1191. https://doi.org/10.3390/vaccines12101191

Chicago

Metko, Muriel, Jason Tonne, Alexa Veliz Rios, Jill Thompson, Haley Mudrick, David Masopust, Rosa Maria Diaz, Michael A. Barry, and Richard G. Vile. 2024. “Intranasal Prime–Boost with Spike Vectors Generates Antibody and T-Cell Responses at the Site of SARS-CoV-2 Infection.” Vaccines 12 (10): 1191. doi:10.3390/vaccines12101191.